Clinical Trials Logo

Clinical Trial Summary

Pentoxyfylline therapy in addition to the standard of care of albumin, midodrine and octreotide therapy is superior to the standard of care alone in the treatment of Type I hepatorenal syndrome in the first 14 days of hospitalization.


Clinical Trial Description

Each hospitalized subject will undergo pre-dosing screening with review of his or her history and physical exam from the day of enrollment and safety assessment to ensure no contraindication to use of PTX. Type I HRS will be defined according to the criteria put forth by the American Association for the Study of Liver Disease as (1) cirrhosis with ascites; (2) serum creatinine greater than 1.5 mg/dL; (3) no improvement of serum creatinine (decrease to a level of 1.5 mg/dL or less) after at least two days with diuretic withdrawal and volume expansion with albumin; (4) absence of shock; (5) no current or recent treatment with nephrotoxic drugs; and (6) absence of parenchymal kidney disease as indicated by proteinuria >500 mg/day, microhematuria (>50 red blood cells per high power field), and/or abnormal renal ultrasonography. Baseline testing will be obtained from hospitalization records, including but not limited to chemistry panel, liver function testing, urinalysis, urine electrolytes, coagulation studies, blood cultures, chest x-ray, diagnostic paracentesis, abdominal ultrasound with Doppler.

Subjects will take either placebo three times a day or pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR <10 for 90 days in addition to standard AMO therapy. Treatment will be continued for 14 days unless a study endpoint has been reached at which time either PTX or placebo will be stopped ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02123576
Study type Interventional
Source University of Virginia
Contact
Status Terminated
Phase N/A
Start date April 2014
Completion date December 31, 2017

See also
  Status Clinical Trial Phase
Completed NCT00370253 - Noradrenalin vs Terlipressin in Hepatorenal Syndrome Phase 3
Completed NCT00359853 - Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis Phase 4
Completed NCT01436500 - Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Phase 2
Completed NCT01143246 - A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin Phase 3
Recruiting NCT05346393 - HRS-AKI Treatment With TIPS in Patients With Cirrhosis N/A
Terminated NCT00734136 - Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome N/A
Terminated NCT00742339 - Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome Phase 2/Phase 3
Recruiting NCT06095440 - A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center
Completed NCT02097784 - Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury N/A
Recruiting NCT04898010 - The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I N/A
Recruiting NCT05875948 - Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome Phase 2
Completed NCT04416282 - Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure. N/A
Recruiting NCT02049125 - Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis N/A
Completed NCT00764049 - Single Pass Albumin Dialysis in Patients With Cirrhosis Phase 1/Phase 2
Completed NCT00089570 - Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1 Phase 3
Withdrawn NCT01587222 - Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure Phase 2
Recruiting NCT02489864 - The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Phase 4
Recruiting NCT02434445 - Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients N/A
Completed NCT02770716 - Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1 Phase 3
Completed NCT05387811 - International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project